ALLO News and Press, Allogene Therapeutics Inc. From 02/22/22

AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report fourth quarter and ye...

Are These The Best Health Care Stocks To Invest In Right Now? As investors consider the current state of the stock market now, health care stocks could become increasingly viable plays. Overall, this would be understandable seeing as markets are having a mostly rocky start t...

miCAR Platform Enables Simultaneous Silencing of Multiple Gene Targets Allogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products SOUTH SAN FRANCISCO, Calif. and GENEVA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc...

• Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene’s Manufacturing Process • Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 202...

Investigation Confirmed the Chromosomal Abnormality in a Single Patient was Not Observed in Any AlloCAR T Product and Not Related to Allogene Manufacturing Process or TALEN ® Gene Editing Clinical Trials Across the AlloCAR T Platform to Resume Pivotal Phase 2 Trial of ALL...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President...

The healthcare stocks in the S&P 500 with a ~2.5% gain outperformed all other sectors in the broader index thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%. Am...

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it entered into a lease agreement t...

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this event. For further details see: Allogene Therapeutics (ALLO) Presents At 63rd Annual Meeting of ASH - Slideshow